Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Kurma Partners has completed the acquisition of BioFund IV, a healthcare services other business in France, for €215m. Kurma Partners acquisitions focus on funding life sciences and healthcare services platforms, supporting portfolio companies across clinical and commercial development. The healthcare M&A strategy behind this private equity acquisition aims to scale operators through a platform acquisition approach in European markets, including Paris-based investment activity. The closed platform acquisition follows Kurma Partners’ fourth Biofund, raised by the Eurazeo-owned healthcare VC investor, with a €250m target not fully reached.
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026